{
    "guideline": {
        "id": "PA166104966",
        "name": "Annotation of DPWG Guideline for tamoxifen and CYP2D6",
        "source": "DPWG",
        "version": 31,
        "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104966",
        "relatedChemicals": [
            {
                "id": "PA451581",
                "name": "tamoxifen",
                "symbol": null
            }
        ],
        "relatedGenes": [
            {
                "id": "PA128",
                "name": "cytochrome P450 family 2 subfamily D member 6",
                "symbol": "CYP2D6"
            }
        ],
        "recommendation": true
    },
    "recommendations": [
        {
            "id": "PA166302762",
            "name": "Recommendation Annotation PA166302762",
            "population": null,
            "classification": {
                "term": "No recommendation",
                "termId": "guidelineStrength:1448526251"
            },
            "relatedChemicals": [
                {
                    "id": "PA451581",
                    "name": "tamoxifen",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104361,
                "html": "<p>The guideline does not provide a recommendation for tamoxifen in normal metabolizers.</p>\n"
            },
            "implications": [
                "The guideline does not provide a description of the impact of a normal metabolizer phenotype on tamoxifen."
            ],
            "lookupKey": {
                "CYP2D6": "1.5"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166302766",
            "name": "Recommendation Annotation PA166302766",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA451581",
                    "name": "tamoxifen",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104365,
                "html": "<p>NO action is needed for this gene-drug interaction.</p>\n"
            },
            "implications": [
                "As a result of the genetic variation, the plasma concentration of the active metabolites 4-hydroxytamoxifen and endoxifen can increase. However, there is no evidence that this results in an increase in the side effects."
            ],
            "lookupKey": {
                "CYP2D6": "3.0"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166302842",
            "name": "Recommendation Annotation PA166302842",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA451581",
                    "name": "tamoxifen",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104441,
                "html": "<p>NO action is needed for this gene-drug interaction.</p>\n"
            },
            "implications": [
                "As a result of the genetic variation, the plasma concentration of the active metabolites 4-hydroxytamoxifen and endoxifen can increase. However, there is no evidence that this results in an increase in the side effects."
            ],
            "lookupKey": {
                "CYP2D6": "\u22655.0"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166302744",
            "name": "Recommendation Annotation PA166302744",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA451581",
                    "name": "tamoxifen",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104343,
                "html": "<ul>\n<li>Select an alternative or measure the endoxifen concentration and increase the dose if necessary, by a factor of 1.5-2. Aromatase inhibitors are a possible alternative for post-menopausal women.</li>\n<li>If TAMOXIFEN is selected: avoid co-medication with CYP2D6 inhibitors such as paroxetine and fluoxetine.</li>\n</ul>\n"
            },
            "implications": [
                "This gene variation reduces the conversion of tamoxifen to the active metabolite endoxifen. This can result in reduced effectiveness."
            ],
            "lookupKey": {
                "CYP2D6": "1.0"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166302726",
            "name": "Recommendation Annotation PA166302726",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA451581",
                    "name": "tamoxifen",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104325,
                "html": "<p>Select an alternative or increase the dose to 40 mg/day and monitor the endoxifen concentration. Studies have demonstrated that PM can achieve an adequate endoxifen concentration when the dose is increased to 40-60 mg/day. Aromatase inhibitors are a possible alternative for post-menopausal women.</p>\n"
            },
            "implications": [
                "This gene variation reduces the conversion of tamoxifen to the active metabolite endoxifen. This can result in reduced effectiveness."
            ],
            "lookupKey": {
                "CYP2D6": "0.0"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166302761",
            "name": "Recommendation Annotation PA166302761",
            "population": null,
            "classification": {
                "term": "No recommendation",
                "termId": "guidelineStrength:1448526251"
            },
            "relatedChemicals": [
                {
                    "id": "PA451581",
                    "name": "tamoxifen",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104360,
                "html": "<p>The guideline does not provide a recommendation for tamoxifen in normal metabolizers.</p>\n"
            },
            "implications": [
                "The guideline does not provide a description of the impact of a normal metabolizer phenotype on tamoxifen."
            ],
            "lookupKey": {
                "CYP2D6": "1.25"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166302821",
            "name": "Recommendation Annotation PA166302821",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA451581",
                    "name": "tamoxifen",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104420,
                "html": "<p>NO action is needed for this gene-drug interaction.</p>\n"
            },
            "implications": [
                "As a result of the genetic variation, the plasma concentration of the active metabolites 4-hydroxytamoxifen and endoxifen can increase. However, there is no evidence that this results in an increase in the side effects."
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.5"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166302765",
            "name": "Recommendation Annotation PA166302765",
            "population": null,
            "classification": {
                "term": "No recommendation",
                "termId": "guidelineStrength:1448526251"
            },
            "relatedChemicals": [
                {
                    "id": "PA451581",
                    "name": "tamoxifen",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104364,
                "html": "<p>The guideline does not provide a recommendation for tamoxifen in normal metabolizers.</p>\n"
            },
            "implications": [
                "The guideline does not provide a description of the impact of a normal metabolizer phenotype on tamoxifen."
            ],
            "lookupKey": {
                "CYP2D6": "2.5"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166302843",
            "name": "Recommendation Annotation PA166302843",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA451581",
                    "name": "tamoxifen",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104442,
                "html": "<p>NO action is needed for this gene-drug interaction.</p>\n"
            },
            "implications": [
                "As a result of the genetic variation, the plasma concentration of the active metabolites 4-hydroxytamoxifen and endoxifen can increase. However, there is no evidence that this results in an increase in the side effects."
            ],
            "lookupKey": {
                "CYP2D6": "\u22656.0"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166302743",
            "name": "Recommendation Annotation PA166302743",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA451581",
                    "name": "tamoxifen",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104342,
                "html": "<ul>\n<li>Select an alternative or measure the endoxifen concentration and increase the dose if necessary, by a factor of 1.5-2. Aromatase inhibitors are a possible alternative for post-menopausal women.</li>\n<li>If TAMOXIFEN is selected: avoid co-medication with CYP2D6 inhibitors such as paroxetine and fluoxetine.</li>\n</ul>\n"
            },
            "implications": [
                "This gene variation reduces the conversion of tamoxifen to the active metabolite endoxifen. This can result in reduced effectiveness."
            ],
            "lookupKey": {
                "CYP2D6": "0.75"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166302764",
            "name": "Recommendation Annotation PA166302764",
            "population": null,
            "classification": {
                "term": "No recommendation",
                "termId": "guidelineStrength:1448526251"
            },
            "relatedChemicals": [
                {
                    "id": "PA451581",
                    "name": "tamoxifen",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104363,
                "html": "<p>The guideline does not provide a recommendation for tamoxifen in normal metabolizers.</p>\n"
            },
            "implications": [
                "The guideline does not provide a description of the impact of a normal metabolizer phenotype on tamoxifen."
            ],
            "lookupKey": {
                "CYP2D6": "2.25"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166302742",
            "name": "Recommendation Annotation PA166302742",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA451581",
                    "name": "tamoxifen",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104341,
                "html": "<ul>\n<li>Select an alternative or measure the endoxifen concentration and increase the dose if necessary, by a factor of 1.5-2. Aromatase inhibitors are a possible alternative for post-menopausal women.</li>\n<li>If TAMOXIFEN is selected: avoid co-medication with CYP2D6 inhibitors such as paroxetine and fluoxetine.</li>\n</ul>\n"
            },
            "implications": [
                "This gene variation reduces the conversion of tamoxifen to the active metabolite endoxifen. This can result in reduced effectiveness."
            ],
            "lookupKey": {
                "CYP2D6": "0.5"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166302781",
            "name": "Recommendation Annotation PA166302781",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA451581",
                    "name": "tamoxifen",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104380,
                "html": "<p>NO action is needed for this gene-drug interaction.</p>\n"
            },
            "implications": [
                "As a result of the genetic variation, the plasma concentration of the active metabolites 4-hydroxytamoxifen and endoxifen can increase. However, there is no evidence that this results in an increase in the side effects."
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.0"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166302801",
            "name": "Recommendation Annotation PA166302801",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA451581",
                    "name": "tamoxifen",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104400,
                "html": "<p>NO action is needed for this gene-drug interaction.</p>\n"
            },
            "implications": [
                "As a result of the genetic variation, the plasma concentration of the active metabolites 4-hydroxytamoxifen and endoxifen can increase. However, there is no evidence that this results in an increase in the side effects."
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.25"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166302763",
            "name": "Recommendation Annotation PA166302763",
            "population": null,
            "classification": {
                "term": "No recommendation",
                "termId": "guidelineStrength:1448526251"
            },
            "relatedChemicals": [
                {
                    "id": "PA451581",
                    "name": "tamoxifen",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104362,
                "html": "<p>The guideline does not provide a recommendation for tamoxifen in normal metabolizers.</p>\n"
            },
            "implications": [
                "The guideline does not provide a description of the impact of a normal metabolizer phenotype on tamoxifen."
            ],
            "lookupKey": {
                "CYP2D6": "2.0"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166302741",
            "name": "Recommendation Annotation PA166302741",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA451581",
                    "name": "tamoxifen",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104340,
                "html": "<ul>\n<li>Select an alternative or measure the endoxifen concentration and increase the dose if necessary, by a factor of 1.5-2. Aromatase inhibitors are a possible alternative for post-menopausal women.</li>\n<li>If TAMOXIFEN is selected: avoid co-medication with CYP2D6 inhibitors such as paroxetine and fluoxetine.</li>\n</ul>\n"
            },
            "implications": [
                "This gene variation reduces the conversion of tamoxifen to the active metabolite endoxifen. This can result in reduced effectiveness."
            ],
            "lookupKey": {
                "CYP2D6": "0.25"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166302767",
            "name": "Recommendation Annotation PA166302767",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA451581",
                    "name": "tamoxifen",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104366,
                "html": "<p>NO action is needed for this gene-drug interaction.</p>\n"
            },
            "implications": [
                "As a result of the genetic variation, the plasma concentration of the active metabolites 4-hydroxytamoxifen and endoxifen can increase. However, there is no evidence that this results in an increase in the side effects."
            ],
            "lookupKey": {
                "CYP2D6": "4.0"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166302841",
            "name": "Recommendation Annotation PA166302841",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA451581",
                    "name": "tamoxifen",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104440,
                "html": "<p>NO action is needed for this gene-drug interaction.</p>\n"
            },
            "implications": [
                "As a result of the genetic variation, the plasma concentration of the active metabolites 4-hydroxytamoxifen and endoxifen can increase. However, there is no evidence that this results in an increase in the side effects."
            ],
            "lookupKey": {
                "CYP2D6": "\u22654.0"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        }
    ],
    "citations": [
        {
            "pmid": "21412232",
            "title": "Pharmacogenetics: from bench to byte--an update of guidelines.",
            "authors": [
                "Swen J J",
                "Nijenhuis M",
                "de Boer A",
                "Grandia L",
                "Maitland-van der Zee A H",
                "Mulder H",
                "Rongen G A P J M",
                "van Schaik R H N",
                "Schalekamp T",
                "Touw D J",
                "van der Weide J",
                "Wilffert B",
                "Deneer V H M",
                "Guchelaar H-J"
            ],
            "journal": "Clinical pharmacology and therapeutics",
            "year": 2011
        }
    ],
    "version": "2024-03-25-16-13"
}